益肾化瘀解毒方对连续不卧床腹膜透析腹膜炎患者血清HMGB-1和hs-CRP水平的影响

Impact of Yishen Huayu Jiedu Formula on Serum HMGB-1 and hs-CRP Levels in Peritonitis Patients Undergone Continuous Ambulatory Peritoneal Dialysis

目的观察益肾化瘀解毒方对连续不卧床腹膜透析(CAPD)腹膜炎患者微炎症状态的影响及其可能作用机制。方法选取60例正在行CAPD治疗且中医辨证为肾虚浊瘀内停证的腹膜炎患者,随机分为治疗组与对照组各30例,两组均进行常规治疗,治疗组加用益肾化瘀解毒方口服,每日1剂,4周为1个疗程,连续治疗2个疗程。评价临床疗效并观察两组患者中医证候积分,检测血清高迁移率族蛋白1(HMGB-1)和超敏C-反应蛋白(hs-CRP)水平。结果治疗组临床疗效有效率为83.34%,对照组为46.67%,治疗组疗效优于对照组(P<0.01)。治疗组治疗后中医证候积分、HMGB-1、hs-CRP均较治疗前显著降低,且均低于对照组(P<0.05或P<0.01)。结论益肾化瘀解毒方能有效改善CAPD腹膜炎患者微炎症状态,其机制可能与降低患者血清HMGB-1和hs-CRP水平有关。

Objective To observe the impact of Yishen Huayu Jiedu Formula（ YSHYJDF） on the microinflammatory states of peritonitis patients undergone continuous ambulatory peritoneal dialysis（ CAPD） and its possible mechanism. Methods Sixty peritonitis patients undergone CAPD with kidney deficiency and phlegm stasis syndrome were randomly divided into treatment group and control group with 30 in each. Routine treatments were applied on both groups. In addition,the treatment group was given YSHYJDF,one dose per day,four weeks a course,for two courses. The clinical efficacy was assessed and TCM syndrome scores were recorded,and the levels of high mobility group box protein 1（ HMGB-1） and high sensitive C-reactive protein（ hs-CRP） were detected for both groups. Results The clinical effective rate in the treatment group（ 83. 34%） was better than that in the control group（ 46. 67%,P 〈0. 01）. After treatment,the TCM syndrome scores as well as levels of HMGB-1 and hs-CRP in the treatment group were significantly decreased,and they were all lower than that in the control group（ P〈0. 05 or P 〈0. 01）. Conclusion Yishen Huayu Jiedu Formula can improve the micro-inflammatory state in peritonitis patient undergone CAPD,which may be associated with lowering the levels of serum HMGB-1 and hs-CRP.